Overview Financials News + Filings Key Docs Charts Ownership Insiders |
CRAWFORD & CO (CRD.B)
|
Add to portfolio |
|
|
Price: |
$7.64
| | Metrics |
OS: |
49.0
|
M
| |
-8
|
% ROE
|
Market cap: |
$374
|
M
| |
-3
|
% ROIC
|
Net debt:
|
$165
|
M
| |
|
|
EV:
|
$539
|
M
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
|
| |
|
|
EBIT
|
$66.3
|
M
| |
8.1
|
x EV/EBIT
|
EPS |
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
Revenues | 1,231.2 | 1,139.2 | 1,016.2 | 1,047.6 | 1,123.0 | 1,163.7 | 1,177.6 | 1,241.5 |
Revenue growth | 8.1% | 12.1% | -3.0% | -6.7% | -3.5% | -1.2% | -5.1% | 2.0% |
Cost of goods sold | 924.9 | 847.4 | 737.3 | 752.8 | 808.0 | 842.2 | 850.1 | 940.4 |
Gross profit | 306.4 | 291.8 | 278.9 | 294.9 | 315.0 | 321.5 | 327.5 | 301.2 |
Gross margin | 24.9% | 25.6% | 27.4% | 28.1% | 28.0% | 27.6% | 27.8% | 24.3% |
Selling, general and administrative | 36.8 | 251.4 | 17.7 | 227.2 | 242.4 | 239.8 | 239.9 | 241.6 |
EBITA | 40.3 | 40.4 | 57.6 | 67.7 | 72.6 | 81.7 | 97.6 | 70.0 |
EBITA margin | 3.3% | 3.5% | 5.7% | 6.5% | 6.5% | 7.0% | 8.3% | 5.6% |
Amortization of intangibles | | | | | | | 10.0 | 10.4 |
EBIT | 40.3 | 40.4 | 57.6 | 67.7 | 72.6 | 81.7 | 87.6 | 59.6 |
EBIT margin | 3.3% | 3.5% | 5.7% | 6.5% | 6.5% | 7.0% | 7.4% | 4.8% |
Pre-tax income | 5.0 | 43.9 | 39.1 | 23.6 | 44.1 | 42.3 | 63.2 | -31.8 |
Income taxes | 23.6 | 13.3 | 12.0 | 14.1 | 18.5 | 15.0 | 25.6 | 13.8 |
Tax rate | 467.3% | 30.4% | 30.7% | 59.7% | 42.0% | 35.6% | 40.4% | |
Net income | -18.5 | 30.5 | 27.1 | 12.5 | 26.0 | 27.7 | 36.0 | -45.5 |
Net margin | -1.5% | 2.7% | 2.7% | 1.2% | 2.3% | 2.4% | 3.1% | -3.7% |
|
Diluted EPS | ($0.38) | $0.57 | $0.51 | $0.23 | $0.46 | $0.49 | $0.64 | ($0.82) |
Shares outstanding (diluted) | 49.3 | 54.0 | 53.4 | 54.1 | 55.9 | 56.8 | 56.2 | 55.3 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|